Xencor (NASDAQ:XNCR) Trading Down 2.7% - Time to Sell?

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) were down 2.7% during trading on Tuesday . The company traded as low as $10.57 and last traded at $10.31. Approximately 20,515 shares traded hands during trading, a decline of 97% from the average daily volume of 621,287 shares. The stock had previously closed at $10.60.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. StockNews.com lowered shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Finally, William Blair started coverage on Xencor in a research report on Monday. They issued an "outperform" rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $33.86.

Xencor Trading Down 1.8 %

The stock has a market cap of $750.42 million, a PE ratio of -3.33 and a beta of 0.90. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock's fifty day moving average price is $11.88 and its 200 day moving average price is $18.49.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, sell-side analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Institutional Investors Weigh In On Xencor

Several large investors have recently bought and sold shares of the business. Sterling Capital Management LLC boosted its holdings in shares of Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Xencor in the fourth quarter worth approximately $34,000. GAMMA Investing LLC grew its position in Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 508 shares during the period. KBC Group NV lifted its holdings in shares of Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 813 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,337 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.